{
    "id": 4232,
    "fullName": "EGFR exon 20 ins",
    "impact": "insertion",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "EGFR exon 20 insertions are in-frame insertions within the kinase domain of Egfr (PMID: 17318210). Exon 20 insertions result in increased Egfr kinase activity, and are associated with low sensitivity to Egfr tyrosine kinase inhibitors (PMID: 17318210, PMID: 24353160, PMID: 28363995).",
            "references": [
                {
                    "id": 1881,
                    "pubMedId": 17318210,
                    "title": "Epidermal growth factor receptor mutations in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17318210"
                },
                {
                    "id": 8567,
                    "pubMedId": 28363995,
                    "title": "Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28363995"
                },
                {
                    "id": 440,
                    "pubMedId": 24353160,
                    "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24353160"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "exon 20 ins",
    "createDate": "03/31/2015",
    "updateDate": "02/28/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2568,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions displayed progressive disease following treatment with Tarceva (erlotinib), and resistance to Tarceva (erlotinib) was replicated in cell culture studies (PMID: 24353160).",
            "molecularProfile": {
                "id": 4039,
                "profileName": "EGFR exon 20 ins"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 440,
                    "pubMedId": 24353160,
                    "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24353160"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7799,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, non-small cell lung cancer patients with EGFR exon 20 insertions (n=29) demonstrated inferior progression-free survival following treatment with first-generation EGFR tyrosine kinase inhibitors such as Iressa (gefitinib), Tarceva (erlotinib), or Icotinib (1.9 months vs. 10.8 months) compared to patients with EGFR L858R and exon 19 deletion mutations (n=592)(PMID: 27468240).",
            "molecularProfile": {
                "id": 4039,
                "profileName": "EGFR exon 20 ins"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6499,
                    "pubMedId": 27468240,
                    "title": "Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27468240"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16303,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, treatment with Luminespib (AUY922) on a clinical trial resulted in a partial response in a non-small cell lung cancer patient harboring an EGFR exon 20 insertion (PMID: 30154228; NCT01124864).",
            "molecularProfile": {
                "id": 4039,
                "profileName": "EGFR exon 20 ins"
            },
            "therapy": {
                "id": 647,
                "therapyName": "Luminespib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14417,
                    "pubMedId": 30154228,
                    "title": "EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30154228"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15371,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Luminespib (AUY922) treatment resulted in partial response or stable disease over 3 months in 38% (11/29) of patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions, with an objective response rate of 17% (5/29), a median progression-free survival of 2.9 months, and a medial overall survival of 13 months (PMID: 30351341; NCT01854034).",
            "molecularProfile": {
                "id": 4039,
                "profileName": "EGFR exon 20 ins"
            },
            "therapy": {
                "id": 647,
                "therapyName": "Luminespib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13126,
                    "pubMedId": 30351341,
                    "title": "Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30351341"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2559,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Luminespib (AUY922) demonstrated safety and preliminary efficacy in EGFR TKI-resistant non-small cell lung cancer patients harboring EGFR exon 20 insertions, with 10% (1/10) of patients achieving partial response and 30% of (3/10) patients achieving stable disease, and a median progression-free survival of 6.1 months (J Clin Oncol 33, 2015 (suppl; abstr 8015)).",
            "molecularProfile": {
                "id": 4039,
                "profileName": "EGFR exon 20 ins"
            },
            "therapy": {
                "id": 647,
                "therapyName": "Luminespib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3291,
                    "pubMedId": null,
                    "title": "Activity of AUY922 in NSCLC patients with EGFR exon 20 insertions.",
                    "url": "http://meetinglibrary.asco.org/content/148352-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17238,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DZD9008 inhibited proliferation of tumor cells expressing EGFR exon 20 insertions in culture, resulted in tumor growth inhibition and regression in patient-derived xenograft (PDX) models (AACR Annual Meeting 2019, Abstract 3081).",
            "molecularProfile": {
                "id": 4039,
                "profileName": "EGFR exon 20 ins"
            },
            "therapy": {
                "id": 8430,
                "therapyName": "DZD9008",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15248,
                    "pubMedId": null,
                    "title": "DZD9008, an oral, wild type selective EGFR inhibitor for the treatment of non-small-cell lung cancer with Exon20 insertion and other activating mutations",
                    "url": "https://www.abstractsonline.com/pp8/#!/6812/presentation/7519"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11153,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions demonstrated a response rate of 11.11% and disease control rate of 44.44%, and a median progression-free survival of 1.9 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).",
            "molecularProfile": {
                "id": 4039,
                "profileName": "EGFR exon 20 ins"
            },
            "therapy": {
                "id": 769,
                "therapyName": "Icotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9121,
                    "pubMedId": null,
                    "title": "Clinical efficacy of icotinib in patients with advanced non-small cell lung cancer harboring EGFR exon 18, 20 and 21 uncommon mutations.",
                    "url": "http://abstracts.asco.org/199/AbstView_199_186649.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7800,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, non-small cell lung cancer patients with EGFR exon 20 insertions (n=29) demonstrated inferior progression-free survival following treatment with first-generation EGFR tyrosine kinase inhibitors such as Iressa (gefitinib), Tarceva (erlotinib), or Icotinib (1.9 months vs. 10.8 months) compared to patients with EGFR L858R and exon 19 deletion mutations (n=592)(PMID: 27468240).",
            "molecularProfile": {
                "id": 4039,
                "profileName": "EGFR exon 20 ins"
            },
            "therapy": {
                "id": 769,
                "therapyName": "Icotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6499,
                    "pubMedId": 27468240,
                    "title": "Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27468240"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2562,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing an EGFR exon 20 insertion mutation had decreased response to Vizimpro (dacomitinib) compared to other EGFR activating mutations, with inhibitory doses exceeding clinically attainable levels (PMID: 18089823, PMID: 21764376).",
            "molecularProfile": {
                "id": 4039,
                "profileName": "EGFR exon 20 ins"
            },
            "therapy": {
                "id": 714,
                "therapyName": "Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3313,
                    "pubMedId": 18089823,
                    "title": "PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18089823"
                },
                {
                    "id": 3314,
                    "pubMedId": 21764376,
                    "title": "EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21764376"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12362,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Poziotinib (HM781-36B) treatment resulted in an overall response rate of 73% (8/11) in non-small cell lung carcinoma patients harboring EGFR exon 20 insertions (PMID: 29162564).",
            "molecularProfile": {
                "id": 4039,
                "profileName": "EGFR exon 20 ins"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10341,
                    "pubMedId": null,
                    "title": "The Preclinical and Clinical Activity of Poziotinib, a Potent, Selective Inhibitor of EGFR Exon 20 Mutant NSCLC",
                    "url": "https://library.iaslc.org/conference-program?product_id=7&author=&category=&date=&session_type=&session=&presentation=&keyword=&available=&page=19"
                },
                {
                    "id": 10586,
                    "pubMedId": 29162564,
                    "title": "Poziotinib Shows Promise for Rare Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29162564"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19677,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, treatment with AP32788 resulted in decreased tumor size in 96% (23/24) of non-small cell lung cancer patients with EGFR exon 20 insertions (Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019) 9007-9007; NCT02716116).",
            "molecularProfile": {
                "id": 4039,
                "profileName": "EGFR exon 20 ins"
            },
            "therapy": {
                "id": 3981,
                "therapyName": "AP32788",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17458,
                    "pubMedId": null,
                    "title": "Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions.",
                    "url": "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.9007"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16853,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAS6417 inhibited growth of transformed cells expressing EGFR exon 20 insertions in culture (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1329).",
            "molecularProfile": {
                "id": 4039,
                "profileName": "EGFR exon 20 ins"
            },
            "therapy": {
                "id": 6994,
                "therapyName": "CLN-081",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14954,
                    "pubMedId": null,
                    "title": "Preclinical evaluation of TAS6417 as a highly effective, pan-mutation-selective EGFR tyrosine kinase inhibitor.",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2561,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing an EGFR exon 20 insertion demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 24065731).",
            "molecularProfile": {
                "id": 4039,
                "profileName": "EGFR exon 20 ins"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 157,
                    "pubMedId": 24065731,
                    "title": "Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24065731"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13994,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, processed Tarloxotinib (TRLX) inhibited Egfr signaling and proliferation of patient-derived lung cancer cells harboring EGFR exon 20 insertions in culture, and the prodrug Tarloxotinib (TRLX) resulted in tumor regression in patient-derived xenograft (PDX) models (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A157).",
            "molecularProfile": {
                "id": 4039,
                "profileName": "EGFR exon 20 ins"
            },
            "therapy": {
                "id": 6986,
                "therapyName": "Tarloxotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11406,
                    "pubMedId": null,
                    "title": "Antitumor activity of tarloxotinib, a hypoxia-activated EGFR TKI, in patient-derived lung cancer cell lines harboring EGFR exon 20 insertions",
                    "url": "http://mct.aacrjournals.org/content/17/1_Supplement/A157"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3364,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Gilotrif (afatinib) treatment resulted in partial response in 33% (1/3), stable disease in 33% (1/3), and progressive disease in 337% (1/3) in non-small cell lung carcinoma patients harboring an EGFR exon 20 insertion mutation (PMID: 26354527).",
            "molecularProfile": {
                "id": 4039,
                "profileName": "EGFR exon 20 ins"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3736,
                    "pubMedId": 26354527,
                    "title": "Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26354527"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19893,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, pooled analysis of non-small cell lung cancer patients treated with Gilotrif (afatinib) demonstrated an objective response rate (ORR) of 24.3% (17/70) and duration of response (DoR) of 11.9 mo in treatment-naive patients with EGFR exon 20 insertions, and an ORR of 14.3% (3/21) and DoR of 3.7 mo in pre-treated patients with EGFR exon 20 insertions (PMID: 31931137).",
            "molecularProfile": {
                "id": 4039,
                "profileName": "EGFR exon 20 ins"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17584,
                    "pubMedId": 31931137,
                    "title": "Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31931137"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2612,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a post-hoc analysis of Phase II and Phase III trials (LUX-Lung2, LUX-Lung 3, LUX-Lung 6), Gilotrif (afatinib) treatment resulted in an objective response rate of 8.7% (2/23) in non-small cell lung cancer patients harboring EGFR exon 20 insertions, with a mean progression-free survival of 2.7 months, and an overall survival of 9.2 months (PMID: 26051236; NCT00525148, NCT00949650, and NCT01121393).",
            "molecularProfile": {
                "id": 4039,
                "profileName": "EGFR exon 20 ins"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3328,
                    "pubMedId": 26051236,
                    "title": "Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26051236"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2567,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell carcinoma cell lines harboring EGFR exon 20 insertions demonstrated resistance to Gilotrif (afatinib) in cell culture (PMID: 24353160).",
            "molecularProfile": {
                "id": 4039,
                "profileName": "EGFR exon 20 ins"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 440,
                    "pubMedId": 24353160,
                    "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24353160"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2569,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions displayed progressive disease following treatment with Iressa (gefitinib), and resistance to Iressa (gefitinib) was replicated in cell culture studies (PMID: 24353160).",
            "molecularProfile": {
                "id": 4039,
                "profileName": "EGFR exon 20 ins"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 440,
                    "pubMedId": 24353160,
                    "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24353160"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7798,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, non-small cell lung cancer patients with EGFR exon 20 insertions (n=29) demonstrated inferior progression-free survival following treatment with first-generation EGFR tyrosine kinase inhibitors such as Iressa (gefitinib), Tarceva (erlotinib), or Icotinib (1.9 months vs. 10.8 months) compared to patients with EGFR L858R and exon 19 deletion mutations (n=592)(PMID: 27468240).",
            "molecularProfile": {
                "id": 4039,
                "profileName": "EGFR exon 20 ins"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6499,
                    "pubMedId": 27468240,
                    "title": "Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27468240"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5655,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EGF816 inhibited growth of transformed cell lines expressing three different EGFR exon 20 insertions in culture (PMID: 26825170).",
            "molecularProfile": {
                "id": 4039,
                "profileName": "EGFR exon 20 ins"
            },
            "therapy": {
                "id": 1309,
                "therapyName": "Nazartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5135,
                    "pubMedId": 26825170,
                    "title": "EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26825170"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5915,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AP32788 inhibited growth of transformed cell lines over expressing EGFR exon 20 insertions in culture, and induced tumor regression in PDX models (AACR, Cancer Res: April 2016; Volume 57, Abstract #2644).",
            "molecularProfile": {
                "id": 4039,
                "profileName": "EGFR exon 20 ins"
            },
            "therapy": {
                "id": 3981,
                "therapyName": "AP32788",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5195,
                    "pubMedId": null,
                    "title": "AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=407e597a-33c8-4936-87f4-08ee4b23e8b9&cKey=34ee7ebf-07c6-40ea-825f-28fb5018ec92&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18125,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SHR-A1307 did not result in tumor regression, however, demonstrated a trend towards inhibition of tumor growth in Erbitux (cetuximab)-resistant patient-derived xenograft (PDX) models of EGFR-positive, and EGFR exon 20 insertion and PIK3CA Y1201H mutated non-small cell lung cancer (PMID: 30962319).",
            "molecularProfile": {
                "id": 32967,
                "profileName": "EGFR exon 20 ins EGFR pos PIK3CA Y1021H"
            },
            "therapy": {
                "id": 8671,
                "therapyName": "SHR-A1307",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16007,
                    "pubMedId": 30962319,
                    "title": "Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30962319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20691,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study, a PIK3CA mutation was identified in a non-small cell lung cancer patient harboring an EGFR exon 20 insertion with primary resistance to icotinib (PMID: 31828849).",
            "molecularProfile": {
                "id": 35286,
                "profileName": "EGFR exon 20 ins PIK3CA mut"
            },
            "therapy": {
                "id": 769,
                "therapyName": "Icotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17988,
                    "pubMedId": 31828849,
                    "title": "Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31828849"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 4039,
            "profileName": "EGFR exon 20 ins",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32967,
            "profileName": "EGFR exon 20 ins EGFR pos PIK3CA Y1021H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35286,
            "profileName": "EGFR exon 20 ins PIK3CA mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}